natgillin/translations-raw huggingface dataset:
Adverse reactions associated with the use of Atripla: Treatment-emergent adverse reactions considered possibly or probably related to Atripla reported in study AI266073 (over 48 weeks; n = 203), which have not been associated with one of the individual components of Atripla, include: Common: - anorexia
Nuspojave povezane s primjenom Atriple: Nuspojave koje su se pojavile tijekom liječenja i za koje se smatra da su moguće ili vjerojatno povezane s Atriplom zabilježene u istraživanju AI266073 (trajanje 48 tjedana, n = 203), a koje nisu povezane s nekom od pojedinačnih komponenti Atriple uključuju:
Adverse reactions associated with the use of ritonavir as a pharmacokinetic enhancer are dependent on the specific co-administered PI.
Nuspojave povezane s primjenom ritonavira kao farmakokinetičkog pojačivača ovise o određenom istodobno primijenjenom IP-.
Adverse reactions associated with the use of ritonavir as a pharmacokinetic enhancer are dependent on the specific co-administered PI.
Nuspojave povezane s primjenom ritonavira kao farmakokinetičkog pojačivača ovise o određenom istodobno primijenjenom IP-u.
Adverse reactions associated with tolvaptan obtained from ADPKD clinical studies are tabulated below.
Nuspojave povezane s tolvaptanom prikupljene iz kliničkih ispitivanja ADPBB-a prikazane su u tablici ispod.
Adverse reactions associated with Xultophy are given below, listed by system organ class and frequency.
Nuspojave povezane s lijekom Xultophy navedene su u nastavku, razvrstane prema organskim sustavima i učestalosti.
Adverse reactions attributable to peripheral venous infusion were phlebitis and thrombosis, both observed at 4% in patients treated with CellCept 500 mg powder for concentrate for solution for infusion.
Nuspojave koje se pripisuju perifernoj intravenskoj infuziji bile su flebitis i tromboza, primijećene u 4% bolesnika liječenih lijekom CellCept 500 mg prašak za koncentrat za otopinu za infuziju.
Adverse reactions by body system and frequency*
Nuspojave prema organskim sustavima i učestalosti
Adverse reactions by system organ class and frequency
Nuspojave prema klasifikaciji organskih sustava i učestalosti pojavljivanja
Adverse reactions by treatment regimen
Nuspojave prema režimu liječenja
Adverse reactions by treatment regimen linagliptin plus metformin
Nuspojave pri režimu liječenja linagliptin plus metformin
Adverse reactions by treatment regimen linagliptin plus metformin plus insulin
Nuspojave pri režimu liječenja linagliptin plus metformin plus inzulin
Adverse reactions by treatment regimen linagliptin plus metformin plus sulphonylurea
Nuspojave pri režimu liječenja linagliptin plus metformin plus sulfonilureja
Adverse reactions by treatment regimen metformin monotherapy
Nuspojave pri režimu liječenja monoterapijom metforminom
Adverse reactions can also occur later with Benlysta, generally 5-10 days after a dose of medicine and include a combination of symptoms such as rash, feeling sick, tiredness, muscle aches, headache, and/or facial swelling.
Kod primjene lijeka Benlysta nuspojave se mogu pojaviti i kasnije, obično 5-10 dana nakon primjene doze lijeka, a uključuju kombinaciju simptoma poput osipa, mučnine, umora, bolova u mišićima, glavobolje i/ili oticanja lica.
Adverse reactions classified by system organ class and MedDRA preferred terms reported in patients who received 5 mg linagliptin in double-blind studies as monotherapy or as add-on therapy are presented per treatment regimen in the table below (see table 1).
Nuspojave, klasificirane prema organskim sustavima i MedDRA terminologiji, prijavljene u bolesnika koji su primali 5 mg linagliptina u dvostruko slijepim ispitivanjima u obliku monoterapije ili dodatne terapije, prikazane su prema režimu liječenja u donjoj tablici (vidjeti tablicu 1).
Adverse reactions considered by investigators to be causally related to ISENTRESS (alone or in combination with other ART) are listed below by System Organ Class.
Nuspojave koje su ispitivači smatrali uzročno povezanima s primjenom lijeka ISENTRESS (samog ili u kombinaciji s drugim ART) navedene su prema klasifikaciji organskih sustava.
Adverse reactions could occur at any timepoint during this period.
Nuspojave se mogu pojaviti u bilo kojem trenutku tijekom tog razdoblja.
Adverse reactions CRIXIVAN
Nuspojave CRIXIVAN
Adverse reactions data in CAPS patients are based on an open-label study of 43 patients with NOMID/CINCA treated with Kineret for up to 5 years, with a total Kineret exposure of 159.8 patient years.
Podaci o nuspojavama u bolesnika s CAPS-om dobiveni su u otvorenom ispitivanju u 43 bolesnika s NOMID/CINCA-om liječenih Kineretom tijekom do 5 godina, pri čemu je ukupna izloženost Kineretu iznosila 159,8 bolesnik godina.
Adverse reactions during treatment course 1
Nuspojave tijekom 1. ciklusa liječenja
Adverse reactions during treatment with erythropoietin are observed predominantly in patients with chronic renal failure or underlying malignancies.
Nuspojave za vrijeme liječenja eritropoetinom primijećene su pretežno kod bolesnika s kroničnim zatajenjem bubrega ili malignim bolestima.
Adverse reactions following administration of RotaTeq in clinical trials and adverse events reported post-marketing (in italics)
Nuspojave nakon primjene cjepiva RotaTeq u kliničkim ispitivanjima i nuspojave prijavljene nakon stavljanja u promet (u kurzivu)
Adverse reactions following the intravenous administration of 64Cu-labelled medicinal products prepared by radiolabelling with Cuprymina, will be dependent on the specific medicinal product being used.
Nuspojave nakon intravenske primjene 64Cu-obilježenih lijekova pripravljenih radioobilježavanjem Cuprymina-om, ovisit će o konkretnom lijeku koji se koristi.
Adverse reactions following the intravenous administration of Lutetium (177Lu)-labelled medicinal products prepared by radiolabelling with Lumark, will be dependent on the specific medicinal product being used.
Nuspojave nakon intravenske primjene lijekova radioaktivno označenih lutecijem (177Lu) pomoću lijeka Lumark ovisit će o specifičnom lijeku koji se primjenjuje.
Adverse reactions following the use of Econor are mainly associated with breeds and cross breeds of Danish and/or Swedish Landrace.
Nuspojave nakon primjene Econora uglavnom su povezane s pasminama i križancima pasmina danskog i/ili švedskog landrasa.
Adverse reactions following the use of Econor are mainly associated with breeds and cross- breeds of Danish and/or Swedish Landrace.
Nuspojave nakon primjene Econora uglavnom su povezane s pasminama i križancima pasmina danskog i/ili švedskog landrasa.
Adverse reactions following this repeat Rienso dosing were similar in character and frequency to those observed following the first two intravenous injections.
Nuspojave nakon ponovljenih doza lijeka Rienso bile su slične po vrsti i učestalosti nuspojavama opaženima nakon prve dvije intravenske injekcije.
Adverse reactions for bivalirudin are listed by system organ class in Table 1.
Nuspojave bivalirudina navedene su prema klasifikaciji organskih sustava u tablici 1.
Adverse reactions for cobicistat-boosted atazanavir were consistent with the safety profile of ritonavir- boosted atazanavir.
Nuspojave na kobicistatom pojačani atazanavir bile su dosljedne sa sigurnosnim profilom ritonavirom pojačanog atazanavira.
Adverse reactions Frequency category
Nuspojave Kategorija učestalosti
Adverse reactions from all clinical trials are listed according to the following frequency:
Nuspojave iz svih kliničkih ispitivanja navedene su prema sljedećoj učestalosti:
Adverse reactions from clinical studies and spontaneous reports with SANCUSO are listed in the table below:
Nuspojave iz kliničkih ispitivanja i spontanih izvješća lijeka SANCUSO navedene su u donjoj tablici.
Adverse reactions from clinical trial in adults and elderly (above 18 years old)
Nuspojave iz kliničkih ispitivanja u odraslih i starijih osoba (od 18 godina naviše)
Adverse reactions from clinical trial in children (6 months to 17 years old) (Study V87P6)
Nuspojave iz kliničkih ispitivanja u djece (u dobi od 6 mjeseci do 17 godina) (Studija V87P6)
Adverse reactions from clinical trial in children aged 6 months to 17 years
Nuspojave iz kliničkih ispitivanja u djece u dobi od 6 mjeseci do 17 godina
Adverse reactions from clinical trials and post-marketing experience in adult and paediatric patients: The following events have been identified as adverse reactions.
Nuspojave iz kliničkih ispitivanja i praćenja nakon stavljanja lijek na tržište kod odraslih i pedijatrijskih bolesnika: Niže navedeni događaji su zabilježeni kao nuspojave.
Adverse reactions from clinical trials and post-marketing experience in adult patients
Nuspojave iz kliničkih ispitivanja i iz postmarketinškog praćenja kod odraslih bolesnika
Adverse reactions from clinical trials and spontaneous reporting, occurring in >1% of patients, are listed in the table below by system organ class and frequency (very common:  1/10, common:
Nuspojave u kliničkim ispitivanjima i iz spontanih prijava bolesnika koje su se javljale kod >1%, bolesnika, navedene su u donjoj tablici prema klasifikaciji organskih sustava i učestalosti (vrlo često:  1/10, često:
Adverse reactions from clinical trials in adults (18 years old and above).
Nuspojave iz kliničkih ispitivanja u odraslih osoba (18 godina i stariji)
Adverse reactions from clinical trials in table 2 were assessed as possibly related to study drug by investigators.
Nuspojave iz kliničkih ispitivanja navedene u tablici 2 su ocijenjene od ispitivača kao vjerojatno povezane s ispitivanjem lijeka.
Adverse reactions from clinical trials with the mock-up vaccine are listed here below (see section 5.1 for more information on mock-up vaccines).
U tekstu koji slijedi navedene su nuspojave iz kliničkih ispitivanja s „mock-up“ cjepivom (za više informacija o „mock-up“ cjepivima vidjeti dio 5.1).
Adverse reactions from clinical trials with the mock-up vaccine are listed here below (see section 5.1 for more information on mock-up vaccines).
U tekstu koji slijedi navedene su nuspojave iz kliničkih ispitivanja sa 'mock-up' cjepivom (za više informacija o 'mock-up' cjepivu vidjeti dio 5.1).
Adverse reactions from clinical trials with the mock-up vaccine Foclivia are listed below.
Nuspojave iz kliničkih ispitivanja s mock-up cjepivom Foclivia navedene su u nastavku.
Adverse reactions from phase III studies during the entire treatment periods
Nuspojave iz ispitivanja faze III prijavljivane tijekom čitavih razdoblja liječenja
Adverse reactions from Prevenar 13 postmarketing experience
Nuspojave iz iskustva nakon stavljanja cjepiva Prevenar13 u promet
Adverse reactions have been included under the appropriate category in the table below according to the highest frequency observed in any of the main clinical trials.
Nuspojave su u tablici navedene pod odgovarajućom kategorijom, prema najvećoj učestalosti opaženoj u u nekom od glavnih kliničkih ispitivanja.
Adverse reactions have been included under the appropriate category in the tables below according to the highest frequency observed in any of the main clinical trials.
Nuspojave su u tablicama navedene pod odgovarajućom kategorijom, prema najvećoj učestalosti opaženoj u u nekom od glavnih kliničkih ispitivanja.
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000).
Nuspojave su poredane po kategorijama učestalosti prema sljedećem pravilu: vrlo često (≥1/10); često (≥1/100 do <1/10); manje često (≥1/1000 do <1/100); rijetko (≥1/10 000 do <1/1000); vrlo rijetko (<1/10 000).
Adverse reactions have been ranked under headings of frequency using the following convention: Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000).
Nuspojave su navedene prema učestalosti uz uporabu sljedeće konvencije: vrlo često (≥1/10), često (≥1/100 do <1/10), manje često (≥1/1000 do <1/100), rijetko (≥1/10 000 do <1/1000).
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to
Nuspojave su podijeljene prema učestalosti koja se definira kao: vrlo često (≥1/10); često (≥1/100 i
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to
Nuspojave su poredane po kategorijama učestalosti prema sljedećem pravilu: vrlo često (≥1/10), često (≥1/100 do <1/10), manje često (≥1/1000 do <1/100), rijetko (≥1/10 000 do
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to
Nuspojave su poredane po kategorijama učestalosti prema sljedećem pravilu: vrlo često (≥1/10), često (≥1/100 i <1/10), manje često (≥1/1000 i <1/100), rijetko (≥1/10 000 i
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000)
Nuspojave su poredane po kategorijama učestalosti prema sljedećem pravilu: vrlo često (≥1/10); često (≥1/100 do <1/10); manje često (≥1/1000 do <1/100); rijetko (≥1/10 000 do <1/1000); vrlo rijetko (<1/10 000).
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000),
Nuspojave su poredane po kategorijama učestalosti prema sljedećem pravilu: vrlo često (≥1/10); često (≥1/100 do <1/10); manje često (≥1/1000 do <1/100); rijetko (≥1/10 000 do <1/1000); vrlo rijetko (<1/10 000).
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).
Nuspojave su klasficirane po učestalosti koristeći sljedeću podjelu: vrlo često (≥ 1/10); često (≥ 1/100 i < 1/10); manje često (≥ 1/1 000 i <1/100); rijetko (≥ 1/10 000 i < 1/1000); vrlo rijetko (< 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).
Nuspojave su klasficirane po učestalosti koristeći sljedeću podjelu: vrlo često (≥ 1/10); često (≥ 1/100 i < 1/10); manje često (≥ 1/1000 i <1/100); rijetko (≥ 1/10 000 i < 1/1000); vrlo rijetko (< 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).
Nuspojave su razvrstane prema učestalosti uz uporabu sljedeće konvencije: vrlo često (≥ 1/10); često (≥ 1/100 do < 1/10); manje često (≥ 1/1000 do < 1/100); rijetko (≥ 1/10 000 do < 1/1000; vrlo rijetko (< 1/10 000); nije poznato (ne može se utvrditi iz dostupnih podataka).
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).
Nuspojave su razvrstane prema učestalosti uz uporabu sljedeće konvencije: vrlo često (≥1/10); često (≥1/100 do <1/10); manje često (≥ 1/1000 do < 1/100); rijetko (≥ 1/10 000 do < 1/1000; vrlo rijetko (<1/10 000); nije poznato (ne može se utvrditi iz dostupnih podataka).
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000).
Nuspojave su poredane po kategorijama učestalosti prema sljedećem pravilu: vrlo često (≥1/10); često (≥1/100 do <1/10); manje često (≥1/1000 do <1/100); rijetko (≥1/10 000 do <1/1000); vrlo rijetko (<1/10 000).
Adverse reactions have generally been mild and transient in nature and have only infrequently required discontinuation of therapy.
Nuspojave su općenito bile blage i prolazne prirode te su samo u rijetkim slučajevima zahtijevale prekid terapije.
Adverse reactions have occurred in pigs following the use of Econor.
Nakon primjene Econora pojavile su se nuspojave u svinja.
Adverse reactions identified are mostly neurological and include seizure, insomnia, anxiety, balance disorder, dizziness, paraesthesia, tremor, headache and asthenia.
Identificirane nuspojave su uglavnom neurološke naravi i uključuju napadaj, nesanicu, anksioznost, poremećaj ravnoteže, omaglicu, parasteziju, tremor, glavobolju i asteniju.
Adverse reactions identified from clinical studies with 24 weeks of treatment with lumacaftor/ivacaftor in patients aged 12 years and older who are homozygous for the F508del mutation in the CFTR gene are presented in Table 2 and are listed by system organ class, frequency, and adverse reactions.
Nuspojave ustanovljene u kliničkim ispitivanjima u kojima su bolesnici u dobi od 12 i više godina, koji su homozigoti za mutaciju F508del gena CFTR, 24 tjedna liječeni lumakaftorom/ivakaftorom, prikazane su u tablici 2, a navedene su prema klasifikaciji organskih sustava, učestalosti i nuspojavama.
Adverse reactions in adults
Nuspojave u odraslih
Adverse reactions in all indications
Nuspojave u svim indikacijama
Adverse reactions in ankylosing spondylitis
Nuspojave kod ankilozantnog spondilitisa
Adverse reactions in clinical studies and from post-marketing experience
Nuspojave u kliničkim ispitivanjima i nakon stavljanja lijeka u promet
Adverse reactions in clinical studies and post-marketing in adult patients
Nuspojave prijavljene u kliničkim ispitivanjima i nakon stavljanja lijeka u promet
Adverse reactions in clinical trials and post-marketing
Nuspojave u kliničkim ispitivanjima i postmarketinškom praćenju
Adverse reactions in dapagliflozin and metformin immediate-release clinical trial and postmarketing dataa
Nuspojave iz kliničkog ispitivanja dapagliflozina i metformina s trenutnim otpuštanjem te iz podataka prikupljenih nakon stavljanja lijeka u prometa
Adverse reactions in ivacaftor-treated patients aged 2 years and older
Nuspojave u bolesnika u dobi od 2 i više godina liječenih ivakaftorom
Adverse reactions in most patients receiving Rapiscan in clinical trials were mild, transient (usually resolving within 30 minutes after receiving Rapiscan), and required no medical intervention.
Nuspojave u većine bolesnika koji su primali Rapiscan tijekom kliničkih ispitivanja bile su blage, prolazne (obično su se povlačile unutar 30 minuta od primjene Rapiscana), i nisu zahtijevale liječenje.
Adverse Reactions in Neurosurgery Study
Nuspojave u neurokirurškom ispitivanju
Adverse reactions in paediatric patients with polyarticular juvenile idiopathic arthritis
Nuspojave u pedijatrijskih bolesnika s poliartikularnim juvenilnim idiopatskim artritisom
Adverse reactions in patients with recurrent or progressive malignant glioma
Nuspojave u bolesnika s recidivirajućim ili progresivnim malignim gliomom
Adverse reactions in patients with spinal cord injury
Nuspojave kod bolesnika s ozljedama leđne moždine
Adverse reactions in patients with spinal cord injury
Nuspojave u bolesnika s ozljedom leđne moždine
Adverse Reactions In Placebo-Controlled Trials and Spontaneous Reports
Nuspojave prikupljene u placebom kontroliranim studijama i spontanim prijavljivanjem
Adverse reactions in plaque psoriasis
Nuspojave kod plak psorijaze
Adverse reactions in psoriatic arthritis
Nuspojave kod psorijatičnog artritisa
Adverse Reactions in Retroperitoneal or Intra-Abdominal Surgery Study
Nuspojave u ispitivanjima u retroperitonealnoj ili intraabdominalnoj kirurgiji
Adverse reactions in table 1 are based on the pooled analysis of the four 26-week placebo-controlled studies (n = 2,313) described above.
Nuspojave u tablici 1 temelje se na analizi udruženih podataka iz četiri 26-tjedna placebom kontrolirana ispitivanja (n=2313) opisana iznad.
Adverse reactions in Table 1 are defined as either any adverse clinical reaction or laboratory abnormality having ≥2% greater incidence (all grades) in the aflibercept treatment group in comparison to the placebo treatment group in the MCRC study including those that do not meet this threshold but were consistent with the anti-VEGF class and were seen in any study with aflibercept.
Nuspojave u Tablici 1 definirane su kao bilo koja klinička nuspojava ili laboratorijsko odstupanje za koje je u ispitivanju MKRK-a incidencija (svih stupnjeva) bila ≥ 2% veća u skupini liječenoj afliberceptom u usporedbi s incidencijom u skupini koja je primala placebo, uključujući nuspojave koje nisu dosegle ovu graničnu vrijednost, ali su odgovarale anti-VEGF razredu i primijećene su u bilo kojem ispitivanju aflibercepta.
Adverse reactions in the week following vaccination from 80 infants 6-11 months old and 82 toddlers 12-35 months old, receiving the 7.5 µg formulation were reported as follows:
U tjednu nakon cijepljenja za 80 dojenčadi u dobi 6- 11 mjeseci i 82 male djece u dobi 12- 35 mjeseci koji su primali formulaciju od 7,5 µg prijavljene su sljedeće nuspojave:
Adverse reactions in the week following vaccination from 87 children 3-8 years old and 95 children and adolescents 9-17 years old receiving the 7.5 µg formulation were reported as follows:
U tjednu nakon cijepljenja za 87 djece u dobi 3-8 godina i 95 djece i adolescenata u dobi 9-17 godina koji su primali formulaciju od 7,5 µg prijavljene su sljedeće nuspojave:
Adverse reactions in the week following vaccination from 87 children 3-8 years old and 95 children and adolescents 9-17 years old, receiving the 7.5 µg formulation were reported as follows:
U tjednu nakon cijepljenja za 87 djece u dobi 3- 8 godina i 95 djece i adolescenata u dobi 9- 17 godina koji su primali formulaciju od 7,5 µg prijavljene su sljedeće nuspojave:
Adverse reactions in Translarna in controlled study of nmDMD
Nuspojave lijeka Translarna u kontroliranom ispitivanju Duchenneove mišićne distrofije (DMD) s besmislenom mutacijom
Adverse Reactions in Vascular Surgery Study
Nuspojave u ispitivanjima u vaskularnoj kirurgiji
adverse reactions is
nuspojave povezane s
Adverse reactions known to be associated with anticholinergic therapy, but not observed with Kentera during clinical studies are anorexia, vomiting, reflux oesophagitis, decreased sweating, heat stroke, decreased lacrimation, mydriasis, tachycardia, arrhythmia, disorientation, poor ability to concentrate, fatigue, nightmares, restlessness, convulsion, intraocular hypertension and induction of glaucoma, confusion, anxiety, paranoia, hallucinations, photosensitivity, erectile dysfunction.
Nuspojave za koje je poznato da su povezane s liječenjem antikolinergicima, ali nisu primijećene uz Kenteru tijekom kliničkih ispitivanja bile su anoreksija, povraćanje, refluks ezofagitis, smanjeno znojenje, toplinski udar, smanjeno suzenje, midrijaza, tahikardija, aritmija, dezorijentiranost, slaba moć koncentracije, umor, noćne more, nemir, konvulzije, intraokularna hipertenzija i indukcija glaukoma, konfuzija, anksioznost, paranoja, halucinacije, preosjetljivost na svjetlo, poremećaj erekcije.